Clinical Trial: Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Fred Hutchinson Cancer Research Center
Information provided by: National Cancer Institute (NCI)


RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy using holmium Ho 166 DOTMP plus melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.

Condition Treatment or Intervention Phase
stage II multiple myeloma
stage III multiple myeloma
stage I multiple myeloma
refractory plasma cell neoplasm
 Drug: holmium Ho 166 DOTMP
 Drug: melphalan
Phase I
Phase II

MedlinePlus related topics:  Immune System and Disorders;   Lymphatic Diseases;   Multiple Myeloma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase I/II Study of Targeted Radiotherapy Using Holmium Ho 166 DOTMP Combined With Melphalan and Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma

Further Study Details: 

Study start: June 1999

OBJECTIVES: I. Determine the maximum tolerated dose of targeted radiotherapy using holmium Ho 166 DOTMP when combined with melphalan and autologous or syngeneic peripheral blood stem cell transplantation in patients with multiple myeloma. II. Determine the response rate and time to progression in patients treated with this regimen.

PROTOCOL OUTLINE: This is a dose escalation, multicenter study of targeted radiotherapy using holmium Ho 166 DOTMP.

Phase I: Autologous or syngeneic peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells. Patients receive an initial test dose of holmium Ho 166 DOTMP IV. Patients with adequate skeletal uptake of the test dose then receive therapeutic dose holmium Ho 166 DOTMP IV over 5-10 minutes for 1-3 days beginning 2 days after test dose infusion and melphalan IV over 20-30 minutes on day -3. PBSC are reinfused beginning a minimum of 24 hours after melphalan infusion and after ongoing radiation to bone marrow falls to less than 1 rad/hour.

Cohorts of 4-7 patients receive escalating doses of targeted radiotherapy using holmium Ho 166 DOTMP until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 7 patients experience dose limiting toxicity.

Phase II: Patients receive holmium Ho 166 DOTMP at the MTD from phase I of the study.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 1 year.


Ages Eligible for Study:  18 Years   -   65 Years



--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: See Disease Characteristics
  • Endocrine therapy: Not specified
  • Radiotherapy: Prior external beam radiotherapy not to exceed 30 Gy to spinal cord or greater than 20% of bone marrow volume
  • Surgery: Not specified
  • Other: At least 1 month since prior bisphosphonates; No other concurrent experimental agents

--Patient Characteristics--

  • Age: 18 to physiologic 65
  • Performance status: Zubrod 0-2
  • Life expectancy: Not severely limited by concurrent illness
  • Hematopoietic: Not specified
  • Hepatic: Bilirubin less than 2 mg/dL; SGPT less than 4 times normal
  • Renal: Creatinine clearance at least 30 mL/min
  • Cardiovascular: No uncontrolled arrhythmias or symptomatic cardiac disease
  • Pulmonary: No symptomatic pulmonary disease FEV1, FVC, and DLCO at least 50% of predicted
  • Other: Not pregnant or nursing; Fertile patients must use effective contraception; HIV negative; No spinal cord compression

Location Information

      Sylvester Cancer Center, University of Miami, Miami,  Florida,  33136,  United States

      University of Texas - MD Anderson Cancer Center, Houston,  Texas,  77030,  United States

      Fred Hutchinson Cancer Research Center, Seattle,  Washington,  98109,  United States

      University of Washington School of Medicine, Seattle,  Washington,  98195,  United States

Study chairs or principal investigators

William I. Bensinger,  Study Chair,  Fred Hutchinson Cancer Research Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000067396; FHCRC-1442.00; NCI-G99-1623; NEORX-9804
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  December 10, 1999 Identifier:  NCT00004158
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005